Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
Condition: Mutant IDH1 Inhibitor Olutasidenib · Sponsor: M.D. Anderson Cancer Center
About this study
To find a recommended combination dose of decitabine and venetoclax that can be given in combination with olutasidenib to participants with AML.
This description comes directly from the study's public registry record.
Talk to the study team
Courtney DiNardo, MD · (713) 794-1141 · cdinardo@mdanderson.org
Always discuss trial participation with your own doctor first.
Locations (5)
| University of Miami | Miami, Florida, United States | Recruiting |
| The University of Kansas Medical Center | Westwood, Kansas, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Roswell Park | Buffalo, New York, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06445959